| Literature DB >> 33876589 |
Joon Young Song1,2, Hee Jin Cheong1,3, Sung Ran Kim2, Sung Eun Lee4, Su Hyun Kim5, Ji Yun Noh1,2, Young Kyung Yoon4,6, Won Suk Choi5,7, Dae Won Park5,7, Jang Wook Sohn4,6, Woo Joo Kim1,2, Min Ja Kim4,6.
Abstract
Hospital-based surveillance for adverse events was conducted on healthcare workers after they received the first dose of coronavirus disease 2019 (COVID-19) vaccine. Among the two new platform vaccines (messenger RNA- and adenoviral vector-based vaccines), the rates of systemic adverse events were significantly higher among adenovirus-vectored vaccine recipients. Fatigue (87.6% vs. 53.8%), myalgia (80.8% vs. 50.0%), headache (72.0% vs. 28.8%), and fever (≥ 38.0°C, 38.7% vs. 0%) were the most common adverse events among adenovirus-vectored vaccine recipients, but most symptoms resolved within 2 days. Both types of COVID-19 vaccines were generally safe, and serious adverse events rarely occurred.Entities:
Keywords: Adverse Event; COVID-19; Safety; Surveillance; Vaccine
Year: 2021 PMID： 33876589 DOI： 10.3346/jkms.2021.36.e110
Source DB: PubMed Journal: J Korean Med Sci ISSN： 1011-8934 Impact factor: 2.153